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Of 19,994 percutaneous transluminal coronary an- 
gioplasty procedures performed in The Netherlands 
between April 1980 and January 1989, the long- 
term follow-up of 454 patients who underwent an- 
gioplasty of 11 saphenous vein bypass graft was 
reviewed. In 46% of patients single graft angio- 
plasty was attempted, and in 64% of patients se- 
quential graft angioplasty was attempted. The clini- 
cal primary success rate was 60%. In-hospital 
mortality was 0.7%, 2.8% of patients sustained a 
procedural myocardial infarction, and 1.3% of pa- 
tients underwent emergency bypass surgery. After 
a follow-up period of 5 years, 74% of patients 
were alive, and 26% were alive and event-free (no 
myocardial infarction, no repeat bypass surgery or 
repeat angioplasty). In patients in whom the initial 
angioplasty attempt was unsuccessful, only 3% 
were event-free at 5 years, versus 27% of success- 
fully dilated patients. The time interval between the 
angioplasty attempt and previous surgery was a 
significant predictor for S-year event-free survival. 
The event-free survival rates for patients who had 
bypass surgery 1 year before, between 1 and 5 
years, and 5 years before angioplasty, were 4526 
and 19%, respectively. Less than one-third of pa- 
tients with previous bypass surgery who had angio- 
plasty of the graft remained event-free after 5 
years. In patients needing angioplasty within 1 
year after bypass surgery, better long-term results 
were achieved. 
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R ecurrence of angina pectoris after aortocoronary bypass surgery in patients with coronary artery disease is either caused by progression of disease 
in the native coronary artery or by the development of 
new narrowings in 21 bypass graft. Because of the in- 
creased morbidity and mortality of coronary reopera- 
tions, it is not surprising that percutaneous transluminal 
balloon angioplasty has been attempted in such patients 
to prevent a reoperation. It has been demonstrated1-9 
that angioplasty can be successfully performed in pal- 
tients with a hemodynamically significant stenosis in a 
venous coronary bypass graft. Little is known about the 
long-term outcome after angioplasty.8,10 In this study, 
we evaluated the long-term clinical effects of balloon 
angioplasty in venous bypass grafts in all 454 patients 
who had undergone such a procedure in The Nether- 
lands between April 1980 (when the first coronary angi- 
oplasty procedure was performed) and January 1989. 
During this time period, a total of 19,994 coronary an- 
gioplasty procedures were performed in the country, of 
which the 454 patients represent 2.7%. 
METHODS 
Between April 1980 and January 1989,454 patients 
underwent angioplasty of at least 1 stenosis of >50% 
diameter in 21 saphenous vein bypass graft. Two hun- 
dred and sixty-four of 454 patients (58.1%) underwent 
an angioplasty either of the bypass graft and 2 1 native 
vessel (38 patients, 14.4%) or of the bypass graft alone 
(226 patients, 85.6%). There were 368 men (81%) and 
86 women (19%) aged 34 to 78 years (mean f standard 
deviation 60 f 8.4). The number of diseased vessels was 
known for 200 of the 454 patients (44.1%). One-vessel 
disease was reported in 15 of 200 patients (7.5%), 2- 
vessel disease in 36 patients (18%) and 3-vessel disease 
in 149 patients (74.5%). In 46% of patients 21 stenoses 
in 21 single graft were dilated, and in 54% of patients 
11 stenoses in a sequential or jump graft were dilated. 
In the patients who underwent single graft angioplasty, 
dilatation was attempted in 69% in grafts to the left 
anterior descending artery, in 21% in grafts to the right 
coronary artery and in 10% in grafts to the circumflex 
artery. The interval between coronary artery bypass sur- 
gery and balloon dilatation (or “graft age”) ranged 
from 6 months to 17 years (mean age 5.7 f 3.8 years) 
(Figure 1). 
Primary success was defined as a reduction of the 
diameter stenosis to <50%, without the occurrence of 
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an acute myocardial infarction, emergency bypass sur- 
gery or death, during the hospital stay of the patients. 
Acute myocardial infarction was defined as the occur- 
rence of new Q waves on the electrocardiogram 130 ms 
or an increase in creatine phosphokinase to >3 times 
normal. Aortocoronary bypass surgery was considered 
to be an emergency when the patient was immediately 
transferred from the cardiac catheterization laboratory 
to the operating room. 
Follow-up data were first obtained by means of a 
letter to the Civil Registration Service to establish sur- 
vival status. If the patients were alive, they were inter- 
viewed by telephone, written questionnaires or outpa- 
tient clinic visits. The following events were considered 
as clinical end points: death, acute myocardial infaro 
tion, reoperation and redilatation. 
All data are presented as mean f 1 standard devi- 
ation. Life tables were actuarially calculated according 
to the Kaplan-Meier method. The generalized Wilcoxon 
test was performed to detect differences between the 
subgroups. A p value <0.05 was considered statistically 
significant. 
RESULTS 
The primary success rate was 90%. In-hospital mor- 
tality was 0.7%. In 2.8% of patients there was evidence 
of a procedural acute myocardial infarction. In 1.3% of 
patients emergency coronary artery bypass urgery was 
performed. 
Actuarial survival for the entire group was 74% 
(f3.4%) at 5 years (Figure 2) and 63% (58%) at 8 
years. However, in patients with initial unsuccessful 
graft angioplasty, 58% were alive at 5 years versus 78% 
of patients in whom graft angioplasty was successful (p 
<O.OOl) (Figure 3). 
After a follow-up period of 5 years, 58% of patients 
were alive and did not sustain a myocardial infarction. 
Thirty-four percent were alive, had no evidence of 
a myocardial infarction, and did not undergo repeat 
bypass surgery. After these 5 years 26% of patients 
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FIGURE 1. The time interval between 
graft angioplasty and previous surgery 
(“graflage”) ranged from 6 months to 17 
years (mean age 5.7 f 3.8 years). 
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FIGURE 2. After the follow-up period of 5 
years, the cumulative probability of surviv- 
al without any cardiac event (death, myo- 
cardial infarction, repeat bypass surgery 
and repsat angioplasty) was 26% 
(+3.3%) for all 464 patients. AMI = acute 
myocardiil infarction; reCABG = repeat 
coronary artery bypass grafting; rePlCA 
= repeat percutaneous transluminal coro- 
nary angioplasty. 
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(~3.3%) were alive and event-free. When only death, 
myocardial infarction and reoperation were considered 
as clinical end points, 34% of patients were alive and 
event-free after 5 years (Figure 2). 
In patients in whom the initial graft angioplasty at- 
tempt was unsuccessful, only 3% were event-free at 5 
years, versus 27% event-free patients in whom initial 
graft angioplasty was successful (p <O.OOOl) (Figure 
4). When grouped by graft age (intervals between by- 
pass surgery and angioplasty <l year, between 1 and 5 
years, and 15 years), there were statistically significant 
differences in 5-year event-free survival rates, namely 
45% for patients who underwent angioplasty within 1 
year after bypass urgery, in contrast o 25 and 19% for 
patients with grafts that had been implanted between 1 
and 5 years, and >5 years before angioplasty, respec- 
tively (p <O.OOS) (Figure 5). 
DISCUSSION 
Between April 1980 and January 1989, 19,994 angi- 
oplasty procedures were performed in The Netherlands. 
In this large collected angioplasty experience, only 2.7% 
of procedures included vein graft dilatation. Many con- 
temporary series have a larger number of patients with 
graft dilatation. However, our reported incidence of 
2.7% is a cumulative number and does not reflect the 
current percentage of patients undergoing raft angio- 
plasty in The Netherlands, which was 4.1% in 1988. In 
1988 the percentage of patients with previous bypass 
surgery undergoing angioplasty of the graft or > 1 more 
native vessel, or both, was 10.3%. 
Furthermore, between 1980 and 1989 there has been 
a progressive recruitment of centers. The number of 
catheterization laboratories performing angioplasty in 
the country increased from 5 to 12. In addition, the ex- 
pansion of the indication of graft angioplasty has been a 
slowly evolving phenomenon, which is also shown by the 
high incidence of bypass operations in The Netherlands. 
Recurrence of angina after coronary artery bypass 
grafting remains a major clinical problem. Failure of 
aortocoronary saphenous vein bypass grafts is generally 
the result of either vein graft stenosis or progressive ath- 
FIGURE 3. The cumulative probability of 
S-year survival grouped by success. In pa- 
tients in whom graft angioplasty had been 
unsuccessful, the probability of survival 
was significantly lower (58%) than in 
those in whom graft angioplasty had been 
successful (78%) (p <O.ool). 
FIGURE 4. The cumulative probability of 
S-year event-free survival grouped by suc- 
cess. In patients in whom the initial graft 
angioplasty attempt had been unsuccess- 
ful, the chance of remaining event-free for 
the first 5 years afler the procedure was 
as low as 3%, compared with 27% for 
those in whom graft angioplasty had been 
successful (p <O.Gwl). 
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TABLE I Success of Saphenous Vein Graft Angioplasty 







1981 Ford et al24 9 89 
1983 Douglas et aI1 62 94 
1984 Block et al* 40 78 
Dorros et als 33 79 
El Gamal et aI” 44 93 
1985 Corbelli et al3 47 91 
Marquis et al4 24 79 
Slysh et al5 6 100 
1986 Reeder et al6 19 84 
1987 Cote et al’ 88 86 
Ernst et allo 33 97 
Pop et also 49 74 
1988 Dorros et al’* 53 83 
Pinkerton et al9 100 93 
Overall 607 87 
PTCA = percutaneous translumlnal coronary angioplasty; SVG = saphenous vein 
graft. 
erosclerotic narrowing of distal native coronary arteries. 
Symptoms of myocardial ischemia will recur or progress 
in about 5% of patients per year.“*12 Early graft nar- 
rowing occurs in up to 10% of grafts within 1 to 2 weeks 
after the operation and 15 to 20% by 1 year.13-15 After 
5 years, up to 25% of grafts are occluded, whereas 52% 
may show stenoses of >70%.15 Stenosis within the first 
month is almost always due to thrombosis and is gener- 
ally related to technical factors such as anastomotic 
narrowing, operative trauma to the vein graft and inad- 
equate distal runoff. l2 It has been demonstrated that 
between 1 month and 1 year postoperatively, intimal fi- 
bromuscular proliferation is the most prevalent form of 
obstruction. Postoperatively, beyond 1 year and particu- 
larly after 3 years, atherosclerosis becomes an impor- 
tant cause of vein graft stenosis and may coexist with 
fibromuscular proliferation. 
Plaques in vein grafts resemble those in native coro- 
nary arteries and are generally soft and friable rather 
than densely fibrotic or calcific. Furthermore, because 
vein grafts tend to be larger than the native coronary 
arteries to which they are anastomosed, and because 
vein graft atherosclerosis often occurs in aneurysmally 
dilated segments, the plaques are generally quite large 
relative to those in native coronary arteries. According- 
ly, atherosclerotic plaques in vein grafts seem particu- 
larly vulnerable to disruption and to embolization of rel- 
atively large fragments. 
Although coronary artery bypass surgery using in- 
ternal mammary artery grafts gives much better long- 
term graft patency rates,7-gJ6 vein grafts will continue 
to be utilized in a majority of surgical candidates with 
multivessel coronary artery disease, because not all ves- 
sels can be bypassed using internal mammary conduits. 
Reoperation is technically more complicated to per- 
form and is generally associated with a higher mor- 
bidity and mortality than a primary operation, and 
achieves ymptomatic relief in only 60 to 70% of pa- 
tients, compared with the 80 to 90% success rate after 
primary operations. The perioperative myocardial in- 
farction rate varies among surgical groups from 2.0 to 
11.5%. The mortality rate after repeat bypass surgery 
varies from 1.2 to 12.5%, and the incidence of reopera- 
tion for bleeding ranges from 3.6 to 10.2%.17m23 
Angioplasty of a saphenous vein bypass graft was 
first performed in 1978 by Ford.24 Since then a number 
of publications have shown the feasibility of this tech- 
nique, with an overall success rate of 87% (Table I). 
Almost the same success rate was seen in our combined 
Dutch series. These rather high success rates probably 
reflect careful patient selection. Long midgraft lesions 
with highly irregular borders were usually avoided be- 
cause of the risk of distal embolization from detached 
material within the grafts, but our angiographic data 
are insufficient o further detail the angiographic ap- 
pearance of the lesions before percutaneous translumin- 
al coronary angioplasty. 
After a follow-up period of 5 years, 74% of 454 pa- 
tients were alive, and only 26% of patients were alive 
and event-free. The number of diseased vessels was 
1 
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FIGURE 5. The cumulative probability of 
survival at 5 years grouped by graftage 
(intervals between coronary artery bypass 
grafting and angioplasty <l year, between 
1 and 5 years, and 15 years). The differ- 
ences in S-year event-free survival rates 
were statistically significank 45% for pa- 
tients who underwent angioplasty within 1 
year after surgery, compared with 25 and 
19% for patients with grafts that had 
been implanted between 1 and 5 years, 
and at 25 years before angioplasty (p 
<O.oos). 
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known for 44.1% of patients, so we could not ascertain 
the presence of multivessel disease as a factor leading to 
late events and reinterventions in the follow-up of these 
patients. Since, in this survey type of investigation, the 
reason for late events or repeat angioplasty or repeat 
bypass surgery is not available, it is difficult to spec- 
ulate on the physiopathologic mechanism responsible 
for these follow-up events. We can not be certain if 
graft restenosis plays a major role in the high incidence 
of late events. 
However, the interval between coronary artery by- 
pass surgery and angioplasty was known in all our pa- 
tients (Figure 1). There were statistically significant (p 
<0.05) differences in event-free survival rates after a 
follow-up period of 5 years among patients who under- 
went bypass surgery within 1 year before angioplasty, 
between 1 and 5 years, and >5 years before angioplasty. 
Event-free survival was reported in 45, 25, and 19% of 
patients, respectively. This finding is in agreement with 
previously published data1-3,7-9,12 that suggest that 
anastomotic lesions respond better to angioplasty than 
lesions that occur later (midgraft). The manner in 
which balloon angioplasty relieves obstructions in vein 
grafts appears to be similar to that described for native 
coronary arteries and is characterized primarily by inti- 
ma1 tears and plaque disruption. Within the first post- 
operative month, balloon angioplasty may be beneficial 
to relieve stenoses, particularly at distal anastomosis 
sites. Angioplasty of aortocoronary saphenous vein by- 
pass grafts >l year of age can be performed with the 
realization that involvement by friable atherosclerosis is 
likely and that atheroembolization represents a risk.25,26 
Eventually, the higher risk of reoperation will make 
the use of less aggressive forms of therapy more attrac- 
tive. Angioplasty of the venous conduits, of the native 
vessels themselves and alternative forms of nonsurgical 
revascularization such as atherectomy, stenting and la- 
ser (balloon) angioplasty may obviate repeat bypass ur- 
gery in some patients. 27,28 However, within the limits of 
our study, we have not been able to look at the results of 
angioplasty of native coronary arteries in patients who 
again become symptomatic after venous bypass graft 
procedures. From published reports it seems that this 
technique also has its limitations.1~3~10,12 
Our data demonstrate that 74% of patients who un- 
dergo angioplasty of a stenosis in a venous graft survive 
5 years after the angioplasty procedure, and that only 
26% remain free of any major event. However, in pa- 
tients needing angioplasty within 1 year after bypass 
surgery, better long-term results can be achieved. Final- 
ly, angioplasty of a venous graft stenosis may be an al- 
ternative to reoperation in some patients with previous 
coronary artery bypass surgery. 
It is the inherent limitation of this type of epidemio- 
logic historical survey, that, although it provides the 
clinical investigator with large numbers, the nonpro- 
spective nature of this investigation does not permit 
one to identify the factors that may improve patient 
selection. 
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